Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Supriya Lifescience Limited
SUPRIYASupriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti"hypertensive, anti-malarial products, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, it also offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, the company is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessasion, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic, stem cell transplantation, and anti-migraine. The company was founded in 1987 and is headquartered in Mumbai, India. Address: 207/208 Udyog Bhavan, Mumbai, India, 400063
Analytics
Zielpreis von Wall Street
48 126.95 INRKGV
33.2291Dividendenrendite
0.13 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen SUPRIYA
Dividenden-Analyse SUPRIYA
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
1 JahrAusschüttungsquote 5-Jahres-Durchschnitt
4 %Verlauf der Dividende SUPRIYA
Bewertung der Aktie SUPRIYA
Finanzen SUPRIYA
Ergebnisse | 2019 | Dynamik |